向日葵(300111.SZ)：子公司参加国家组织集采药品协议期满品种接续采购拟中选

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., has participated in the national centralized procurement for drugs whose agreements are expiring, with some products expected to be selected for procurement [1] Group 1: Procurement Participation - Zhejiang Beid Pharmaceutical has submitted applications for the national centralized procurement for drugs whose agreements are expiring, excluding insulin [1] - The results of the procurement selection were published by the procurement office on February 10, 2026, indicating that some products from Beid Pharmaceutical are likely to be selected [1] Group 2: Selected Products and Financial Impact - The products expected to be selected include Clarithromycin tablets and Simvastatin tablets, both of which are included in the national medical insurance catalog [1] - For the year 2024, the sales revenue of Clarithromycin tablets is projected to be 37.18 million yuan, accounting for 11.29% of the company's main business income during the same period [1] - The sales revenue of Simvastatin tablets is projected to be 1.71 million yuan, representing 0.52% of the company's main business income during the same period [1]